Cravatt Benjamin — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Cravatt Benjamin has filed 1 SEC Form 4 filing across 1 company in the last 90 days.

Profile

Cravatt Benjamin is listed as a director of ALNYLAM Pharmaceuticals, Inc. as of the SEC filing dated 2026-06-03. He is widely recognized in the scientific community as a leader in chemical biology, notably for contributions to proteomics and activity-based protein profiling (ABPP). His appointment to the ALNYLAM board aligns with the company’s focus on RNA therapeutics and the integration of advanced biological technologies into drug discovery.

Board memberships

• ALNYLAM Pharmaceuticals, Inc.

Awards & honors

• Pioneered or significantly contributed to activity-based protein profiling (ABPP) in chemical biology
• Recognized for advancing proteomics techniques relevant to drug discovery

Companies — Last 90 Days

• ALNYLAM PHARMACEUTICALS, INC. (ALNY) — 1 filings, last 2026-06-03

Frequently Asked Questions

Who is Cravatt Benjamin?

Cravatt Benjamin is listed as a director of ALNYLAM Pharmaceuticals, Inc. as of the SEC filing dated 2026-06-03. He is widely recognized in the scientific community as a leader in chemical biology, notably for contributions to proteomics and activity-based protein profiling (ABPP). His appointment to the ALNYLAM board aligns with the company’s focus on RNA therapeutics and the …

How many SEC Form 4 filings has Cravatt Benjamin submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Where can I see all of Cravatt Benjamin's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

• What is SEC Form 4?
• How to read insider buying signals
• Understanding Rule 10b5-1 trading plans
• Browse all insiders
• Most active insiders this week